Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Coronavirus Notebook: Moderna To Build UK Vaccines Plant, US Approves First MAb For COVID-19

Executive Summary

Sanofi/GSK’s VidPrevtyn Beta has become the seventh COVID-19 vaccine to be approved by the UK regulator, the MHRA.

You may also be interested in...



Reform Of MHRA & Clinical Trials Needed To Unlock UK’s ‘Medical & Scientific Potential’

Moderna says that if the right investments are made in reforming the Medicines and Healthcare products Regulatory Agency, the National Health Service and other public health bodies, the UK will be in a strong position to mitigate “future shocks” in the health care system.

Sanofi & GSK Win COVID-19 Vaccine Approval In EU Using Immunobridging Trials

The European Medicines Agency said it was possible to use immunobridging studies to authorize COVID-19 vaccines now that a number of COVID-19 vaccines authorized in the EU are proven to be safe and effective and can be used as comparators in trials.

Changes To EU Pharma Reform: More Questions Than Answers?

In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS147495

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel